Clinical trials: Urinary Complications
Urinary Tract Infections, Acute Pyelonephritis
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
- Trial name
- CERTAIN-1 (NCT03840148)
- Testing
- Cefepime/VNRX-5133 (taniborbactam), Meropenem
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 661 people
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Superficial Bladder Cancer
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Gemcitabine has been shown to be highly effective and well tolerated in the first and second line therapy, as a single agent or in combination therapy for treatment of metastatic transitional cell carcinoma.
- Trial name
- NCT00192049
- Testing
- Gemcitabine, mitomycin C
- Where
- 5 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder, Urinary Incontinence
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urge Incontinence
- Trial name
- SOLAR (NCT00337558)
- Testing
- Solifenacin succinate, Simplified bladder training
- Where
- 64 sites in Australia, Belgium and 9 more
- Volunteers
- 643 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world…
- Trial name
- NCT05067478
- Testing
- Vibegron
- Where
- 64 sites in United States
- Volunteers
- 403 people
- Sponsor
- Urovant Sciences GmbH
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Urinary Retention
Alfuzosin Versus Placebo in Acute Urinary Retention
The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with…
- Trial name
- ALF-RIK (NCT00453908)
- Testing
- Alfuzosin
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Sanofi
Kidney Transplant, Kidney Failure
Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors.
- Conditions
- Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures, End Stage Renal Disease (ESRD)
- Trial name
- NEWHOPE (NCT07792317)
- Testing
- Omnisol organ preservation solution
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Vivalyx GmbH
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Chronic Glomerulonephritis, Diabetic Nephropathy
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
The treatment period was 16 weeks, the initial dose, 5 mg, was unforcedly titrated to 10 mg, 20 mg and 40 mg after confirming tolerance at weeks 4, 8 and 12.
- Trial name
- NCT00914524
- Testing
- olmesartan medoxomil
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Overactive Bladder Syndrome, Urinary Urge Incontinence
Cycling Study With the Axonics System
A prospective, multi-center, study comparing continuous sacral neuromodulation (SNM) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the Axonics System.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation
- Trial name
- NCT05543382
- Testing
- Axonics System
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Axonics, Inc.
Overactive Bladder, Fecal Incontinence
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
To collect physiological signals at several timepoints during the therapy evaluation period.
- Conditions
- Overactive Bladder, Fecal Incontinence, Urinary Retention
- Trial name
- PEER 2 (NCT05200923)
- Testing
- Sacral Neuromodulation
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- MedtronicNeuro
Bladder Cancer
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.
- Trial name
- NCT03125460
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 424 people
- Sponsor
- Cepheid
Overactive Bladder (OAB)
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
- Trial name
- NCT02294396
- Testing
- Mirabegron tablet, Solifenacin tablet, Propiverine tablet
- Where
- 7 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Astellas Pharma Inc
Bladder Cancer
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
The purpose of this study is to evaluate efficacy of gemcitabine and cisplatin combined with either radical cystectomy or radiotherapy in the treatment of bladder cancer.
- Trial name
- NCT00490880
- Testing
- gemcitabine, cisplatin, radical cystectomy
- Where
- Poland
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
- Trial name
- NCT00321477
- Testing
- GW679769 oral tablets
- Where
- 58 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Stress Urinary Incontinence
An Investigation With an Intra-vaginal Device for Stress Urinary Incontinence
This is a prospective, randomized, controlled, two-armed multi-center pre-market trial. Nighty-six (96) subjects will be recruited at sites in Sweden.
- Trial name
- NCT03186651
- Testing
- TVS
- Where
- 4 sites in Sweden
- Volunteers
- 97 people
- Sponsor
- Invent Medic Sweden AB
Bladder Cancer
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
This is a phase II, single center open label to determine safety, dose tolerance, PK and PD of the recommended Phase 2 dose (RP2D) of CPX-POM administered in patients with any newly diagnosed or recurrent bladder tumors.
- Trial name
- NCT04525131
- Testing
- CPX-POM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- CicloMed LLC
Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone.
- Conditions
- Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms
- Trial name
- NCT00315237
- Testing
- vinflunine and best supportive care
- Where
- 10 sites in Canada
- Volunteers
- 364 people
- Sponsor
- Pierre Fabre Medicament
Overactive Bladder, Detrusor Overactivity
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
The purpose of this study is to assess if the study drug, Vardenafil (approved by Health Authorities is available on the market for treatment of erectile dysfunction) has an effect on bladder function and micturition frequency.
- Trial name
- NCT00478881
- Testing
- Vardenafil HCl (Levitra, BAY38-9456)
- Where
- 55 sites in Belgium, Canada and 11 more
- Volunteers
- 397 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.